Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

96.250
-1.800-1.84%
Volume:8.90M
Turnover:843.31M
Market Cap:167.96B
PE:204.79
High:96.600
Open:94.200
Low:92.400
Close:98.050
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:0.87
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:6.92
PE(LYR):204.79
PS:9.13

Loading ...

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

GlobeNewswire
·
Jul 14

Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?

Simply Wall St.
·
Jul 12

Nomura Adjusts Innovent Biologics' Price Target to HK$123.17 From HK$114.64, Keeps at Buy

MT Newswires Live
·
Jul 10

Bank of America Securities Foresees Valuation Re-rating for Chinese Pharma Sector Driven by Active Licensing Deals, Raises Innovent Bio Target to HK$119.2

Stock News
·
Jul 10

Biotech Stocks Surge as New National Essential Drug List Includes Innovative Therapies

Stock News
·
Jul 10

Movement Alert|Innovent Biologics Rises 3.13% in Regular Trading, Zhongtai International Reaffirms Buy Rating with Target Price of HK$134.50

Market Focus
·
Jul 10

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

INNOVENT BIO Issues Approximately 1.88 Million Shares Under Employee Scheme

Stock News
·
Jul 07

INNOVENT BIO Issues 38.87k New Shares in June; Public Float Remains Compliant

Bulletin Express
·
Jul 07

Innovent Biologics Files HKEX Next-day Return, Share Capital Rises by 1,882,334 Shares

Reuters
·
Jul 07

Movement Alert|Innovent Biologics Falls 3.04% in Regular Trading, Trading at HKD 87.9

Market Focus
·
Jul 07

Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization

Stock News
·
Jul 06

Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%

Tiger Newspress
·
Jul 06

Movement Alert|Innovent Biologics Rises 3.19% in Regular Trading, Eli Lilly Partnership and Mazdutide Insurance Review Catalysts Continue

Market Focus
·
Jul 06

Is Innovent Biologics (SEHK:1801) Still Cheap As Verzenios Rights Lift Growth Hopes?

Simply Wall St.
·
Jul 03

Movement Alert|Innovent Biologics Rises 3.57% in Regular Trading, Lilly Partnership and Mazdutide Insurance Review Catalysts Continue

Market Focus
·
Jul 03

Movement Alert|Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress

Market Focus
·
Jul 02

China's Innovent Biologics Gains Commercialization Rights for Eli Lilly Breast Cancer Drug

Reuters
·
Jun 30

Innovent, Lilly Team up to Commercialize Verzenios in Mainland China

Reuters
·
Jun 30

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

THOMSON REUTERS
·
Jun 30